(Q26825301)

Judith E Raber-Durlacher

2

object named as

Judith E Raber-Durlacher

1 reference

author name string

Christine B Boers-Doets

1

1 reference

Nathaniel S Treister

3

1 reference

Joel B Epstein

4

1 reference

Anniek BP Arends

5

1 reference

Diede R Wiersma

6

1 reference

Rajesh V Lalla

7

1 reference

Richard M Logan

8

1 reference

Nielka P van Erp

9

1 reference

language of work or name

1 reference

December 2013

1 reference

1 reference

9

1 reference

PubMed

issue

12

1 reference

PubMed

page(s)

1883-92

1 reference

Current development of mTOR inhibitors as anticancer agents

PubMed

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

Oral complications of targeted cancer therapies: a narrative literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

New developments in management of oral mucositis in patients with head and neck cancer or receiving targeted anticancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

Management of oral mucositis in patients who have cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

Managing stomatitis in patients treated with Mammalian target of rapamycin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

Clinical presentation and management of mTOR inhibitor-associated stomatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

A systematic review of viral infections associated with oral involvement in cancer patients: a spotlight on Herpesviridea

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

Clinical practice. Aphthous ulceration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

Dysfunction of CD4+CD25high T regulatory cells in patients with recurrent aphthous stomatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

The multiple facets of mTOR in immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

The multifunctional role of mTOR in innate immunity: implications for transplant immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

Alimentary mucositis: putting the guidelines into practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

Experiences with the FACT-EGFRI-18 instrument in EGFRI-associated mucocutaneous adverse events.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

Vanderbilt Head and Neck Symptom Survey version 2.0: report of the development and initial testing of a subscale for assessment of oral health

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

Updated clinical practice guidelines for the prevention and treatment of mucositis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

mTOR inhibitor-associated dermatologic and mucosal problems

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

Oral bacteria and yeasts in relationship to oral ulcerations in hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141

Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.141